Fujirebio was established in 1950 and specializes in the development diagnostic biomarkers for identifying metabolic, neurodegenerative, and infectious diseases as well as cancer. Fujirebio is currently recruiting for a clinical trial (NCT03174938) that will evaluate the safety and efficacy of a diagnostic biomarker it has developed for detecting Alzheimer’s disease in blood.
×
Fujirebio � Biomarker development for Alzheimer's Disease
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.
Powered by MMD